ArticleInfectious diseases of poverty2026
Drug-resistant tuberculosis in Nepal: the sixth national prevalence drug-resistant survey, 2024.
Article in Infectious diseases of poverty, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a major public health challenge in Nepal, characterized by increasing drug-resistant TB (DR-TB) and constrained surveillance capacity. The sixth national DR-TB prevalence survey was therefore implemented to address this gap. This study aimed to estimate the national prevalence of DR-TB and identify risk factors among new and previously treated pulmonary TB patients.
methodsA national cross-sectional survey was conducted from December 2022 to January 2024, enrolling bacteriologically confirmed pulmonary TB patients using stratified cluster sampling at 49 diagnostic centers. Phenotypic and genotypic drug sensitivity testing was performed on 1768 Mycobacterium tuberculosis-confirmed samples. Logistic regression analysis estimated DR-TB prevalence and its associated risk factors.
resultsRifampicin resistance was identified in 2.2% [95% confidence interval (CI) 1.4-3.6] of new TB patients and 10.1% (95% CI 5.1-19) of previously treated patients. In total, 9.4% exhibited resistance to at least one first-line drug, with isoniazid exhibiting the highest resistance rate. Within the rifampicin-resistant TB (RR-TB) group, resistance to moxifloxacin was more prevalent among newly diagnosed patients than previously treated patients at both critical concentrations (55.3% vs. 33.3% at 0.25 µg/ml; 34.2% vs. 11.1% at 1 µg/ml). Previous TB treatment emerged as the strongest predictor of rifampicin resistance [adjusted odds ratio (aOR) = 4.1, 95% CI 2.6-6.4].
conclusionsThe prevalence of RR/multidrug-resistant (MDR)-TB in Nepal remains stable compared with previous surveys. However, a high rate of fluoroquinolone resistance among new patients underscores the urgent need for improved antibiotic stewardship and expanded drug-susceptibility testing services. These findings provide essential evidence to guide national TB control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.